

IX. BIBLIOGRAFÍA

- Acehan D, Jiang X, Morgan DG, Heuser JE, Wang X, Akey CW (2002): Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. *Mol Cell* 9:423-32.
- Adhikary S, Eilers M (2005): Transcriptional regulation and transformation by Myc proteins. *Nat Rev Mol Cell Biol* 6:635-45.
- Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ (2004): Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. *FEBS Lett* 571:43-9.
- Ai H, Ihlemann J, Hellsten Y, Lauritzen HP, Hardie DG, Galbo H, Ploug T (2002): Effect of fiber type and nutritional state on AICAR- and contraction-stimulated glucose transport in rat muscle. *Am J Physiol Endocrinol Metab* 282:E1291-300.
- Alessi DR, Sakamoto K, Bayascas JR (2006): LKB1-dependent signaling pathways. *Annu Rev Biochem* 75:137-63.
- Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M (2008): Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. *Endocr Relat Cancer* 15:833-9.
- Almaca J, Kongsuphol P, Hieke B, Ousingsawat J, Viollet B, Schreiber R, Amaral MD, Kunzelmann K (2009): AMPK controls epithelial Na⁽⁺⁾ channels through Nedd4-2 and causes an epithelial phenotype when mutated. *Pflugers Arch* 458:713-21.
- Altenberg B, Greulich KO (2004): Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. *Genomics* 84:1014-20.
- Ambrosini G, Adida C, Altieri DC (1997): A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. *Nat Med* 3:917-21.
- Andersson Y, Le H, Juell S, Fodstad O (2006): AMP-activated protein kinase protects against anti-epidermal growth factor receptor-Pseudomonas exotoxin A immunotoxin-induced MA11 breast cancer cell death. *Mol Cancer Ther* 5:1050-9.
- Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semchenko AV, Provinciali M, Re F, Franceschi C (2005): Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. *Exp Gerontol* 40:685-93.
- Ashkenazi A (2002): Targeting death and decoy receptors of the tumour-necrosis factor superfamily. *Nat Rev Cancer* 2:420-30.
- Ashkenazi A, Dixit VM (1998): Death receptors: signaling and modulation. *Science* 281:1305-8.
- Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH (1999): Safety and antitumor activity of recombinant soluble Apo2 ligand. *J Clin Invest* 104:155-62.
- Austin CD, Lawrence DA, Peden AA, Varfolomeev EE, Totpal K, De Maziere AM, Klumperman J, Arnott D, Pham V, Scheller RH,

- Ashkenazi A (2006): Death-receptor activation halts clathrin-dependent endocytosis. *Proc Natl Acad Sci U S A* 103:10283-8.
- Bader AG, Kang S, Zhao L, Vogt PK (2005): Oncogenic PI3K deregulates transcription and translation. *Nat Rev Cancer* 5:921-9.
- Bain J, McLauchlan H, Elliott M, Cohen P (2003): The specificities of protein kinase inhibitors: an update. *Biochem J* 371:199-204.
- Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, Loetscher H, Lesslauer W (1993): Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. *Cell* 73:431-45.
- Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME (2004): CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. *Embo J* 23:3175-85.
- Bateman A (1997): The structure of a domain common to archaeobacteria and the homocystinuria disease protein. *Trends Biochem Sci* 22:12-3.
- Baud V, Karin M (2001): Signal transduction by tumor necrosis factor and its relatives. *Trends Cell Biol* 11:372-7.
- Beg ZH, Allmann DW, Gibson DM (1973): Modulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with cAMP and with protein fractions of rat liver cytosol. *Biochem Biophys Res Commun* 54:1362-9.
- Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW (2001): SP600125, an anthranyrazolone inhibitor of Jun N-terminal kinase. *Proc Natl Acad Sci U S A* 98:13681-6.
- Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH (2006): TIGAR, a p53-inducible regulator of glycolysis and apoptosis. *Cell* 126:107-20.
- Bertazza L, Mocellin S (2008): Tumor necrosis factor (TNF) biology and cell death. *Front Biosci* 13:2736-43.
- Bertin J, Armstrong RC, Otilie S, Martin DA, Wang Y, Banks S, Wang GH, Senkevich TG, Alnemri ES, Moss B, Lenardo MJ, Tomaselli KJ, Cohen JI (1997): Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. *Proc Natl Acad Sci U S A* 94:1172-6.
- Bhalla V, Oyster NM, Fitch AC, Wijngaarden MA, Neumann D, Schlattner U, Pearce D, Hallows KR (2006): AMP-activated kinase inhibits the epithelial Na⁺ channel through functional regulation of the ubiquitin ligase Nedd4-2. *J Biol Chem* 281:26159-69.
- Bhardwaj A, Aggarwal BB (2003): Receptor-mediated choreography of life and death. *J Clin Immunol* 23:317-32.
- Bhoj VG, Chen ZJ (2009): Ubiquitylation in innate and adaptive immunity. *Nature* 458:430-7.
- Black RA, Kronheim SR, Sleath PR (1989): Activation of interleukin-1 beta by a co-induced protease. *FEBS Lett* 247:386-90.
- Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani

- N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP (1997): A metalloproteinase disintegrin that releases tumour-necrosis factor- α from cells. *Nature* 385:729-33.
- Blankenship JW, Varfolomeev E, Goncharov T, Fedorova AV, Kirkpatrick DS, Izrael-Tomasevic A, Phu L, Arnott D, Aghajan M, Zobel K, Bazan JF, Fairbrother WJ, Deshayes K, Vucic D (2009): Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1). *Biochem J* 417:149-60.
- Bockbrader KM, Tan M, Sun Y (2005): A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. *Oncogene* 24:7381-8.
- Bodmer JL, Schneider P, Tschopp J (2002): The molecular architecture of the TNF superfamily. *Trends Biochem Sci* 27:19-26.
- Bolden JE, Peart MJ, Johnstone RW (2006): Anticancer activities of histone deacetylase inhibitors. *Nat Rev Drug Discov* 5:769-84.
- Bortul R, Tazzari PL, Cappellini A, Tabellini G, Billi AM, Bareggi R, Manzoli L, Cocco L, Martelli AM (2003): Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation. *Leukemia* 17:379-89.
- Bose S, Chandran S, Mirocha JM, Bose N (2006): The Akt pathway in human breast cancer: a tissue-array-based analysis. *Mod Pathol* 19:238-45.
- Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006): Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. *Diabetes Care* 29:254-8.
- Bremer E, Samplonius DF, van Genne L, Dijkstra MH, Kroesen BJ, de Leij LF, Helfrich W (2005): Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. *J Biol Chem* 280:10025-33.
- Bright NJ, Carling D, Thornton C (2008): Investigating the regulation of brain-specific kinases 1 and 2 by phosphorylation. *J Biol Chem* 283:14946-54.
- Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL (1994): A mammalian protein targeted by G1-arresting rapamycin-receptor complex. *Nature* 369:756-8.
- Browne GJ, Finn SG, Proud CG (2004): Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398. *J Biol Chem* 279:12220-31.
- Brummelkamp TR, Nijman SM, Dirac AM, Bernards R (2003): Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. *Nature* 424:797-801.

- Budanov AV, Karin M (2008): p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. *Cell* 134:451-60.
- Burke RE (2008): Programmed cell death and new discoveries in the genetics of parkinsonism. *J Neurochem* 104:875-90.
- Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB (2007): Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. *Cancer Res* 67:6745-52.
- Cailleau R, Olive M, Cruciger QV (1978): Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. *In Vitro* 14:911-5.
- Cailleau R, Young R, Olive M, Reeves WJ, Jr. (1974): Breast tumor cell lines from pleural effusions. *J Natl Cancer Inst* 53:661-74.
- Campas C, Lopez JM, Santidrian AF, Barragan M, Bellosillo B, Colomer D, Gil J (2003): Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. *Blood* 101:3674-80.
- Campbell IK, Roberts LJ, Wicks IP (2003): Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis. *Immunol Cell Biol* 81:354-66.
- Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV (1996): TRAF6 is a signal transducer for interleukin-1. *Nature* 383:443-6.
- Carling D, Zammit VA, Hardie DG (1987): A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. *FEBS Lett* 223:217-22.
- Carlson CA, Kim KH (1973): Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. *J Biol Chem* 248:378-80.
- Cipriani G, Rapizzi E, Vannacci A, Rizzuto R, Moroni F, Chiarugi A (2005): Nuclear poly(ADP-ribose) polymerase-1 rapidly triggers mitochondrial dysfunction. *J Biol Chem* 280:17227-34.
- Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo MJ, Chan FK (2005): Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. *Proc Natl Acad Sci U S A* 102:18099-104.
- Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV (1998): Fc receptors are required in passive and active immunity to melanoma. *Proc Natl Acad Sci U S A* 95:652-6.
- Clynes RA, Towers TL, Presta LG, Ravetch JV (2000): Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. *Nat Med* 6:443-6.
- Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, Dickinson R, Adler A, Gagne G, Iyengar R, Zhao G, Marsh K, Kym P, Jung P, Camp HS, Frevert E (2006): Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. *Cell Metab* 3:403-16.

- Corallini F, Rimondi E, Secchiero P (2008): TRAIL and osteoprotegerin: a role in endothelial physiopathology? *Front Biosci* 13:135-47.
- Cornforth AN, Davis JS, Khanifar E, Nastiuk KL, Krolewski JJ (2008): FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells. *Oncogene* 27:4422-33.
- Corton JM, Gillespie JG, Hawley SA, Hardie DG (1995): 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? *Eur J Biochem* 229:558-65.
- Crabtree HG (1928): The carbohydrate metabolism of certain pathological overgrowths. *Biochem J* 22:1289-98.
- Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ (2006): TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. *Immunol Cell Biol* 84:87-98.
- Crino PB, Nathanson KL, Henske EP (2006): The tuberous sclerosis complex. *N Engl J Med* 355:1345-56.
- Crute BE, Seefeld K, Gamble J, Kemp BE, Witters LA (1998): Functional domains of the alpha1 catalytic subunit of the AMP-activated protein kinase. *J Biol Chem* 273:35347-54.
- Chang DW, Xing Z, Pan Y, Algeciras-Schimmich A, Barnhart BC, Yaish-Ohad S, Peter ME, Yang X (2002): c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. *Embo J* 21:3704-14.
- Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, Liu YC, Karin M (2006): The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. *Cell* 124:601-13.
- Chawla-Sarkar M, Bauer JA, Lupica JA, Morrison BH, Tang Z, Oates RK, Almasan A, DiDonato JA, Borden EC, Lindner DJ (2003): Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. *J Biol Chem* 278:39461-9.
- Chen G, Goeddel DV (2002): TNF-R1 signaling: a beautiful pathway. *Science* 296:1634-5.
- Chen HC, Bandyopadhyay G, Sajan MP, Kanoh Y, Standaert M, Farese RV, Jr., Farese RV (2002): Activation of the ERK pathway and atypical protein kinase C isoforms in exercise- and aminoimidazole-4-carboxamide-1-beta-D-ribose (AICAR)-stimulated glucose transport. *J Biol Chem* 277:23554-62.
- Chen L, Jiao ZH, Zheng LS, Zhang YY, Xie ST, Wang ZX, Wu JW (2009): Structural insight into the autoinhibition mechanism of AMP-activated protein kinase. *Nature* 459:1146-9.
- Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD (1994): Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. *Science* 263:1759-62.
- Cheung PC, Nebreda AR, Cohen P (2004): TAB3, a new binding partner of the protein kinase TAK1. *Biochem J* 378:27-34.

- Cheung PC, Salt IP, Davies SP, Hardie DG, Carling D (2000): Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. *Biochem J* 346 Pt 3:659-69.
- Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, Rehemtulla A (2000): Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. *Proc Natl Acad Sci U S A* 97:1754-9.
- Chittenden T, Flemington C, Houghton AB, Ebb RG, Gallo GJ, Elangovan B, Chinnadurai G, Lutz RJ (1995): A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. *Embo J* 14:5589-96.
- Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, Chan FK (2009): Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. *Cell* 137:1112-23.
- Choi HC, Song P, Xie Z, Wu Y, Xu J, Zhang M, Dong Y, Wang S, Lau K, Zou MH (2008): Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo. *J Biol Chem* 283:20186-97.
- Chung JY, Park YC, Ye H, Wu H (2002): All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. *J Cell Sci* 115:679-88.
- Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, Ashkenazi A, Kim KJ (2001): Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. *J Immunol* 166:4891-8.
- da Silva Xavier G, Leclerc I, Salt IP, Doiron B, Hardie DG, Kahn A, Rutter GA (2000): Role of AMP-activated protein kinase in the regulation by glucose of islet beta cell gene expression. *Proc Natl Acad Sci U S A* 97:4023-8.
- Daniel T, Carling D (2002): Functional analysis of mutations in the gamma 2 subunit of AMP-activated protein kinase associated with cardiac hypertrophy and Wolff-Parkinson-White syndrome. *J Biol Chem* 277:51017-24.
- Daniels RA, Turley H, Kimberley FC, Liu XS, Mongkolsapaya J, Ch'En P, Xu XN, Jin BQ, Pezzella F, Screaton GR (2005): Expression of TRAIL and TRAIL receptors in normal and malignant tissues. *Cell Res* 15:430-8.
- Davidoff F (1971): Effects of guanidine derivatives on mitochondrial function. 3. The mechanism of phenethylbiguanide accumulation and its relationship to in vitro respiratory inhibition. *J Biol Chem* 246:4017-27.
- Davies SP, Carling D, Hardie DG (1989): Tissue distribution of the AMP-activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay. *Eur J Biochem* 186:123-8.

- Day P, Sharff A, Parra L, Cleasby A, Williams M, Horer S, Nar H, Redemann N, Tickle I, Yon J (2007): Structure of a CBS-domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP and ZMP. *Acta Crystallogr D Biol Crystallogr* 63:587-96.
- Debnath J, Muthuswamy SK, Brugge JS (2003): Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. *Methods* 30:256-68.
- Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG (1997): The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. *Immunity* 7:813-20.
- Degterev A, Boyce M, Yuan J (2003): A decade of caspases. *Oncogene* 22:8543-67.
- Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C, Chen ZJ (2000): Activation of the I kappa B kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. *Cell* 103:351-61.
- Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC (1999): Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. *Embo J* 18:5242-51.
- Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC (1998): IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. *Embo J* 17:2215-23.
- Deveraux QL, Takahashi R, Salvesen GS, Reed JC (1997): X-linked IAP is a direct inhibitor of cell-death proteases. *Nature* 388:300-4.
- Djerbi M, Darreh-Shori T, Zhivotovsky B, Grandien A (2001): Characterization of the human FLICE-inhibitory protein locus and comparison of the anti-apoptotic activity of four different flip isoforms. *Scand J Immunol* 54:180-9.
- Downey JM, Cohen MV, Ytrehus K, Liu Y (1994): Cellular mechanisms in ischemic preconditioning: the role of adenosine and protein kinase C. *Ann N Y Acad Sci* 723:82-98.
- Du C, Fang M, Li Y, Li L, Wang X (2000): Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. *Cell* 102:33-42.
- Duckett CS, Nava VE, Gedrich RW, Clem RJ, Van Dongen JL, Gilfillan MC, Shiels H, Hardwick JM, Thompson CB (1996): A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. *Embo J* 15:2685-94.
- Dumitru CA, Carpinteiro A, Trarbach T, Hengge UR, Gulbins E (2007): Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. *Apoptosis* 12:1533-41.
- Dykens JA, Jamieson J, Marroquin L, Nadanaciva S, Billis PA, Will Y (2008): Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2

- cells and human hepatocytes in vitro. *Toxicol Appl Pharmacol* 233:203-10.
- Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ (2006): Activation of IKK by TNF α requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. *Mol Cell* 22:245-57.
- Eckelman BP, Salvesen GS, Scott FL (2006): Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. *EMBO Rep* 7:988-94.
- Eckhart L, Ballaun C, Uthman A, Kittel C, Stichenwirth M, Buchberger M, Fischer H, Sipos W, Tschachler E (2005): Identification and characterization of a novel mammalian caspase with proapoptotic activity. *J Biol Chem* 280:35077-80.
- Edinger AL, Thompson CB (2003): Defective autophagy leads to cancer. *Cancer Cell* 4:422-4.
- Edinger AL, Thompson CB (2004): Death by design: apoptosis, necrosis and autophagy. *Curr Opin Cell Biol* 16:663-9.
- El-Zawahry A, McKillop J, Voelkel-Johnson C (2005): Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. *BMC Cancer* 5:2.
- Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR (1998): Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. *J Biol Chem* 273:14363-7.
- Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S (1998): A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. *Nature* 391:43-50.
- Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005): Metformin and reduced risk of cancer in diabetic patients. *BMJ* 330:1304-5.
- Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM (2000): A receptor for phosphatidylserine-specific clearance of apoptotic cells. *Nature* 405:85-90.
- Fantin VR, St-Pierre J, Leder P (2006): Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. *Cancer Cell* 9:425-34.
- Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, Lowe S, Levine AJ (2007): The regulation of AMPK β 1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. *Cancer Res* 67:3043-53.
- Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P (2007): RIP1, a kinase on the crossroads of a cell's decision to live or die. *Cell Death Differ* 14:400-10.
- Fryer LG, Parbu-Patel A, Carling D (2002): The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. *J Biol Chem* 277:25226-32.

- Fuentes-Prior P, Salvesen GS (2004): The protein structures that shape caspase activity, specificity, activation and inhibition. *Biochem J* 384:201-32.
- Fulda S, Debatin KM (2006): Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. *Oncogene* 25:4798-811.
- Gambhir SS (2002): Molecular imaging of cancer with positron emission tomography. *Nat Rev Cancer* 2:683-93.
- Garber K (2006): Energy deregulation: licensing tumors to grow. *Science* 312:1158-9.
- Gatenby RA, Gillies RJ (2007): Glycolysis in cancer: a potential target for therapy. *Int J Biochem Cell Biol* 39:1358-66.
- Golks A, Brenner D, Fritsch C, Krammer PH, Lavrik IN (2005): c-FLIPR, a new regulator of death receptor-induced apoptosis. *J Biol Chem* 280:14507-13.
- Gollob MH, Seger JJ, Gollob TN, Tapscott T, Gonzales O, Bachinski L, Roberts R (2001): Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. *Circulation* 104:3030-3.
- Goodwin PJ, Ligibel JA, Stambolic V (2009): Metformin in breast cancer: time for action. *J Clin Oncol* 27:3271-3.
- Goransson O, McBride A, Hawley SA, Ross FA, Shpiro N, Foretz M, Viollet B, Hardie DG, Sakamoto K (2007): Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. *J Biol Chem* 282:32549-60.
- Green DR, Evan GI (2002): A matter of life and death. *Cancer Cell* 1:19-30.
- Guenther GG, Peralta ER, Rosales KR, Wong SY, Siskind LJ, Edinger AL (2008): Ceramide starves cells to death by downregulating nutrient transporter proteins. *Proc Natl Acad Sci U S A* 105:17402-7.
- Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P, Bhalla K (2004): Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. *Cancer Res* 64:2580-9.
- Guppy M, Greiner E, Brand K (1993): The role of the Crabtree effect and an endogenous fuel in the energy metabolism of resting and proliferating thymocytes. *Eur J Biochem* 212:95-9.
- Gupta AK, Lee YJ, Galoforo SS, Berns CM, Martinez AA, Corry PM, Wu X, Guan KL (1997): Differential effect of glucose deprivation on MAPK activation in drug sensitive human breast carcinoma MCF-7 and multidrug resistant MCF-7/ADR cells. *Mol Cell Biochem* 170:23-30.
- Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ (2008): AMPK phosphorylation of raptor mediates a metabolic checkpoint. *Mol Cell* 30:214-26.

- Gyrd-Hansen M, Darding M, Miasari M, Santoro MM, Zender L, Xue W, Tenev T, da Fonseca PC, Zvelebil M, Bujnicki JM, Lowe S, Silke J, Meier P (2008): IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. *Nat Cell Biol* 10:1309-17.
- Ha HC, Snyder SH (1999): Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. *Proc Natl Acad Sci U S A* 96:13978-82.
- Hallstrom TC, Mori S, Nevins JR (2008): An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. *Cancer Cell* 13:11-22.
- Hamilton SR, Stapleton D, O'Donnell JB, Jr., Kung JT, Dalal SR, Kemp BE, Witters LA (2001): An activating mutation in the gamma1 subunit of the AMP-activated protein kinase. *FEBS Lett* 500:163-8.
- Hanahan D, Weinberg RA (2000): The hallmarks of cancer. *Cell* 100:57-70.
- Hardie DG (2007): AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. *Nat Rev Mol Cell Biol* 8:774-85.
- Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF (2004): The TSC1-2 tumor suppressor controls insulin-P13K signaling via regulation of IRS proteins. *J Cell Biol* 166:213-23.
- Hartford CM, Ratain MJ (2007): Rapamycin: something old, something new, sometimes borrowed and now renewed. *Clin Pharmacol Ther* 82:381-8.
- Harvey AJ, Soliman H, Kaiser WJ, Miller LK (1997): Anti- and pro-apoptotic activities of baculovirus and *Drosophila* IAPs in an insect cell line. *Cell Death Differ* 4:733-44.
- Hauser HP, Bardroff M, Pyrowolakis G, Jentsch S (1998): A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors. *J Cell Biol* 141:1415-22.
- Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR, Hardie DG (2003): Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. *J Biol* 2:24.
- Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D, Hardie DG (1996): Characterization of the AMP-activated protein kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. *J Biol Chem* 271:27879-87.
- Hawley SA, Gadalla AE, Olsen GS, Hardie DG (2002): The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. *Diabetes* 51:2420-5.
- Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, Frenguelli BG, Hardie DG (2005): Calmodulin-dependent protein kinase

- kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. *Cell Metab* 2:9-19.
- Hayakawa Y, Screpanti V, Yagita H, Grandien A, Ljunggren HG, Smyth MJ, Chambers BJ (2004): NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. *J Immunol* 172:123-9.
- He Q, Lee DI, Rong R, Yu M, Luo X, Klein M, El-Deiry WS, Huang Y, Hussain A, Sheikh MS (2002): Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. *Oncogene* 21:2623-33.
- He S, Wang L, Miao L, Wang T, Du F, Zhao L, Wang X (2009): Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. *Cell* 137:1100-11.
- Hegde R, Srinivasula SM, Zhang Z, Wassell R, Mukattash R, Cilenti L, DuBois G, Lazebnik Y, Zervos AS, Fernandes-Alnemri T, Alnemri ES (2002): Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. *J Biol Chem* 277:432-8.
- Held J, Schulze-Osthoff K (2001): Potential and caveats of TRAIL in cancer therapy. *Drug Resist Updat* 4:243-52.
- Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Hoglund P, Jarvinen H, Kristo P, Pelin K, Ridanpaa M, Salovaara R, Toro T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, de la Chapelle A, Aaltonen LA (1998): A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. *Nature* 391:184-7.
- Herrero-Martin G, Hoyer-Hansen M, Garcia-Garcia C, Fumarola C, Farkas T, Lopez-Rivas A, Jaattela M (2009): TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. *Embo J* 28:1532.
- Hitomi J, Katayama T, Eguchi Y, Kudo T, Taniguchi M, Koyama Y, Manabe T, Yamagishi S, Bando Y, Imaizumi K, Tsujimoto Y, Tohyama M (2004): Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death. *J Cell Biol* 165:347-56.
- Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, Bodmer JL, Schneider P, Seed B, Tschopp J (2000): Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. *Nat Immunol* 1:489-95.
- Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, Harris CC (1994): Database of p53 gene somatic mutations in human tumors and cell lines. *Nucleic Acids Res* 22:3551-5.
- Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L, Lavoigne A, Hue L, Proud C, Rider M (2002): Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. *Curr Biol* 12:1419-23.

- Hougardy BM, Maduro JH, van der Zee AG, de Groot DJ, van den Heuvel FA, de Vries EG, de Jong S (2006): Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. *Int J Cancer* 118:1892-900.
- Hsu H, Shu HB, Pan MG, Goeddel DV (1996): TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. *Cell* 84:299-308.
- Hsu YT, Wolter KG, Youle RJ (1997): Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. *Proc Natl Acad Sci U S A* 94:3668-72.
- Hu S, Vincenz C, Buller M, Dixit VM (1997a): A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis. *J Biol Chem* 272:9621-4.
- Hu S, Vincenz C, Ni J, Gentz R, Dixit VM (1997b): I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. *J Biol Chem* 272:17255-7.
- Huang X, Wullschlegel S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, McBurnie W, Fleming S, Alessi DR (2008): Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. *Biochem J* 412:211-21.
- Hudson ER, Pan DA, James J, Lucocq JM, Hawley SA, Green KA, Baba O, Terashima T, Hardie DG (2003): A novel domain in AMP-activated protein kinase causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias. *Curr Biol* 13:861-6.
- Hughes MA, Harper N, Butterworth M, Cain K, Cohen GM, MacFarlane M (2009): Reconstitution of the death-inducing signaling complex reveals a substrate switch that determines CD95-mediated death or survival. *Mol Cell* 35:265-79.
- Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI (2000): Mechanism by which metformin reduces glucose production in type 2 diabetes. *Diabetes* 49:2063-9.
- Hurley RL, Anderson KA, Franzone JM, Kemp BE, Means AR, Witters LA (2005): The Ca²⁺/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. *J Biol Chem* 280:29060-6.
- Hymowitz SG, O'Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A, de Vos AM, Kelley RF (2000): A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. *Biochemistry* 39:633-40.
- Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, Zhou T (2001): Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. *Nat Med* 7:954-60.

- Ido Y, Carling D, Ruderman N (2002): Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. *Diabetes* 51:159-67.
- Igney FH, Krammer PH (2002): Death and anti-death: tumour resistance to apoptosis. *Nat Rev Cancer* 2:277-88.
- Imamura K, Ogura T, Kishimoto A, Kaminishi M, Esumi H (2001): Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. *Biochem Biophys Res Commun* 287:562-7.
- Inagaki M, Omori E, Kim JY, Komatsu Y, Scott G, Ray MK, Yamada G, Matsumoto K, Mishina Y, Ninomiya-Tsuji J (2008): TAK1-binding protein 1, TAB1, mediates osmotic stress-induced TAK1 activation but is dispensable for TAK1-mediated cytokine signaling. *J Biol Chem* 283:33080-6.
- Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002): TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. *Nat Cell Biol* 4:648-57.
- Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL (2006): TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. *Cell* 126:955-68.
- Inoki K, Zhu T, Guan KL (2003): TSC2 mediates cellular energy response to control cell growth and survival. *Cell* 115:577-90.
- Irmeler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J (1997): Inhibition of death receptor signals by cellular FLIP. *Nature* 388:190-5.
- Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V, Micic D, Trajkovic V (2007): Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. *Cell Mol Life Sci* 64:1290-302.
- Iseli TJ, Walter M, van Denderen BJ, Katsis F, Witters LA, Kemp BE, Michell BJ, Stapleton D (2005): AMP-activated protein kinase beta subunit tethers alpha and gamma subunits via its C-terminal sequence (186-270). *J Biol Chem* 280:13395-400.
- Ishimura N, Isomoto H, Bronk SF, Gores GJ (2006): Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. *Am J Physiol Gastrointest Liver Physiol* 290:G129-36.
- Ishitani T, Takaesu G, Ninomiya-Tsuji J, Shibuya H, Gaynor RB, Matsumoto K (2003): Role of the TAB2-related protein TAB3 in IL-1 and TNF signaling. *Embo J* 22:6277-88.
- Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN (2004): Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. *Nat Cell Biol* 6:1122-8.

- Janicke RU, Sprengart ML, Wati MR, Porter AG (1998): Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. *J Biol Chem* 273:9357-60.
- Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD, Griffith TS, Green DR, Schoenberger SP (2005): CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. *Nature* 434:88-93.
- Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Muller O, Back W, Zimmer M (1998): Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. *Nat Genet* 18:38-43.
- Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Janne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK (2007): LKB1 modulates lung cancer differentiation and metastasis. *Nature* 448:807-10.
- Jiang CC, Chen LH, Gillespie S, Kiejda KA, Mhaidat N, Wang YF, Thorne R, Zhang XD, Hersey P (2007): Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. *Cancer Res* 67:5880-8.
- Jin S, White E (2007): Role of autophagy in cancer: management of metabolic stress. *Autophagy* 3:28-31.
- Jin Z, El-Deiry WS (2006): Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. *Mol Cell Biol* 26:8136-48.
- Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR, Ashkenazi A (2009): Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. *Cell* 137:721-35.
- Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM (2009): Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. *J Clin Oncol* 27:3297-302.
- Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A, Kraft AS (2003): The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. *Oncogene* 22:4953-63.
- Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB (2005): AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. *Mol Cell* 18:283-93.
- Jung SN, Park IJ, Kim MJ, Kang I, Choe W, Kim SS, Ha J (2009): Down-regulation of AMP-activated protein kinase sensitizes DU145

- carcinoma to Fas-induced apoptosis via c-FLIP degradation. *Exp Cell Res* 315:2433-41.
- Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T (2000): LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. *Embo J* 19:5720-8.
- Kanayama A, Seth RB, Sun L, Ea CK, Hong M, Shaito A, Chiu YH, Deng L, Chen ZJ (2004): TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. *Mol Cell* 15:535-48.
- Karikari CA, Roy I, Tryggestad E, Feldmann G, Pinilla C, Welsh K, Reed JC, Armour EP, Wong J, Herman J, Rakheja D, Maitra A (2007): Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. *Mol Cancer Ther* 6:957-66.
- Kasof GM, Gomes BC (2001): Livin, a novel inhibitor of apoptosis protein family member. *J Biol Chem* 276:3238-46.
- Kaufmann SH, Vaux DL (2003): Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. *Oncogene* 22:7414-30.
- Kaunisto A, Kochin V, Asaoka T, Mikhailov A, Poukkula M, Meinander A, Eriksson JE (2009): PKC-mediated phosphorylation regulates c-FLIP ubiquitylation and stability. *Cell Death Differ* 16:1215-26.
- Kefas BA, Cai Y, Ling Z, Heimberg H, Hue L, Pipeleers D, Van de Castele M (2003): AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. *J Mol Endocrinol* 30:151-61.
- Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A (2005): Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. *J Biol Chem* 280:2205-12.
- Kelley SK, Ashkenazi A (2004): Targeting death receptors in cancer with Apo2L/TRAIL. *Curr Opin Pharmacol* 4:333-9.
- Kemp BE (2004): Bateman domains and adenosine derivatives form a binding contract. *J Clin Invest* 113:182-4.
- Kerr JF, Wyllie AH, Currie AR (1972): Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer* 26:239-57.
- Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, Logsdon CD, Abbruzzese JL, McConkey DJ (2006): Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. *Mol Cancer Ther* 5:2251-60.
- Kim JE, Ahn MW, Baek SH, Lee IK, Kim YW, Kim JY, Dan JM, Park SY (2008): AMPK activator, AICAR, inhibits palmitate-induced apoptosis in osteoblast. *Bone* 43:394-404.

- Kim KM, Song JJ, An JY, Kwon YT, Lee YJ (2005): Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression. *J Biol Chem* 280:41047-56.
- Kimberley FC, Lobito AA, Siegel RM, Screaton GR (2007): Falling into TRAPS—receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. *Arthritis Res Ther* 9:217.
- Kimberley FC, Screaton GR (2004): Following a TRAIL: update on a ligand and its five receptors. *Cell Res* 14:359-72.
- Kimura N, Tokunaga C, Dalal S, Richardson C, Yoshino K, Hara K, Kemp BE, Witters LA, Mimura O, Yonezawa K (2003): A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. *Genes Cells* 8:65-79.
- King TD, Song L, Jope RS (2006): AMP-activated protein kinase (AMPK) activating agents cause dephosphorylation of Akt and glycogen synthase kinase-3. *Biochem Pharmacol* 71:1637-47.
- Klionsky DJ, Emr SD (2000): Autophagy as a regulated pathway of cellular degradation. *Science* 290:1717-21.
- Ko YH, Park S, Jin H, Woo H, Lee H, Park C, Kim K (2007): Granzyme B leakage-induced apoptosis is a crucial mechanism of cell death in nasal-type NK/T-cell lymphoma. *Lab Invest* 87:241-50.
- Koenig U, Eckhart L, Tschachler E (2001): Evidence that caspase-13 is not a human but a bovine gene. *Biochem Biophys Res Commun* 285:1150-4.
- Koschny R, Walczak H, Ganten TM (2007): The promise of TRAIL—potential and risks of a novel anticancer therapy. *J Mol Med* 85:923-35.
- Kostura MJ, Tocci MJ, Limjuco G, Chin J, Cameron P, Hillman AG, Chartrain NA, Schmidt JA (1989): Identification of a monocyte specific pre-interleukin 1 beta convertase activity. *Proc Natl Acad Sci U S A* 86:5227-31.
- Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G (2003): The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. *Nature* 424:801-5.
- Krawiec BJ, Nystrom GJ, Frost RA, Jefferson LS, Lang CH (2007): AMP-activated protein kinase agonists increase mRNA content of the muscle-specific ubiquitin ligases MAFbx and MuRF1 in C2C12 cells. *Am J Physiol Endocrinol Metab* 292:E1555-67.
- Kreuz S, Siegmund D, Rumpf JJ, Samel D, Leverkus M, Janssen O, Hacker G, Dittrich-Breiholz O, Kracht M, Scheurich P, Wajant H (2004): NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. *J Cell Biol* 166:369-80.
- Kreuz S, Siegmund D, Scheurich P, Wajant H (2001): NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. *Mol Cell Biol* 21:3964-73.
- Krikos A, Laherty CD, Dixit VM (1992): Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. *J Biol Chem* 267:17971-6.

- Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S (2001): Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. *J Biol Chem* 276:20633-40.
- Kundu M, Pathak SK, Kumawat K, Basu S, Chatterjee G, Pathak S, Noguchi T, Takeda K, Ichijo H, Thien CB, Langdon WY, Basu J (2009): A TNF- and c-Cbl-dependent FLIP(S)-degradation pathway and its function in Mycobacterium tuberculosis-induced macrophage apoptosis. *Nat Immunol* 10:918-26.
- Kurtoglu M, Lampidis TJ (2009): From delocalized lipophilic cations to hypoxia: blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors. *Mol Nutr Food Res* 53:68-75.
- Lagace M, Xuan JY, Young SS, McRoberts C, Maier J, Rajcan-Separovic E, Korneluk RG (2001): Genomic organization of the X-linked inhibitor of apoptosis and identification of a novel testis-specific transcript. *Genomics* 77:181-8.
- Lage R, Dieguez C, Vidal-Puig A, Lopez M (2008): AMPK: a metabolic gauge regulating whole-body energy homeostasis. *Trends Mol Med* 14:539-49.
- Lamkanfi M, Declercq W, Kalai M, Saelens X, Vandenaabeele P (2002): Alice in caspase land. A phylogenetic analysis of caspases from worm to man. *Cell Death Differ* 9:358-61.
- Lane MD, Moss J, Polakis SE (1974): Acetyl coenzyme A carboxylase. *Curr Top Cell Regul* 8:139-95.
- Lang T, Yu L, Tu Q, Jiang J, Chen Z, Xin Y, Liu G, Zhao S (2000): Molecular cloning, genomic organization, and mapping of PRKAG2, a heart abundant gamma2 subunit of 5'-AMP-activated protein kinase, to human chromosome 7q36. *Genomics* 70:258-63.
- Lasfargues EY, Coutinho WG, Redfield ES (1978): Isolation of two human tumor epithelial cell lines from solid breast carcinomas. *J Natl Cancer Inst* 61:967-78.
- Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A (2001): Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. *Nat Med* 7:383-5.
- Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, Ma A (2000): Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. *Science* 289:2350-4.
- Lee JM, Bernstein A (1995): Apoptosis, cancer and the p53 tumour suppressor gene. *Cancer Metastasis Rev* 14:149-61.
- Legler DF, Micheau O, Doucey MA, Tschopp J, Bron C (2003): Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation. *Immunity* 18:655-64.
- Leist M, Jaattela M (2001): Four deaths and a funeral: from caspases to alternative mechanisms. *Nat Rev Mol Cell Biol* 2:589-98.

- Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ (2002): Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. *Cancer Cell* 2:183-92.
- Levine B, Klionsky DJ (2004): Development by self-digestion: molecular mechanisms and biological functions of autophagy. *Dev Cell* 6:463-77.
- Li H, Zhu H, Xu CJ, Yuan J (1998): Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. *Cell* 94:491-501.
- Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG (2004): A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. *Science* 305:1471-4.
- Li LY, Luo X, Wang X (2001): Endonuclease G is an apoptotic DNase when released from mitochondria. *Nature* 412:95-9.
- Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C, Mukaida N (2006): Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. *Cancer Res* 66:6741-7.
- Lin JH, Deng G, Huang Q, Morser J (2000): KIAP, a novel member of the inhibitor of apoptosis protein family. *Biochem Biophys Res Commun* 279:820-31.
- Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, Williams S, Wiegmans AP, Dear AE, Scott CL, Pellegrini M, Wei A, Richon VM, Marks PA, Lowe SW, Smyth MJ, Johnstone RW (2007): Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. *Proc Natl Acad Sci U S A* 104:8071-6.
- Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, Farahani R, McLean M, Ikeda JE, MacKenzie A, Korneluk RG (1996): Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. *Nature* 379:349-53.
- Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY (2007): The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. *Cancer Res* 67:4981-8.
- Liu ZG, Hsu H, Goeddel DV, Karin M (1996): Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. *Cell* 87:565-76.
- Longnus SL, Wambolt RB, Parsons HL, Brownsey RW, Allard MF (2003): 5-Aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. *Am J Physiol Regul Integr Comp Physiol* 284:R936-44.
- Lopez JM, Santidrian AF, Campas C, Gil J (2003): 5-Aminoimidazole-4-carboxamide riboside induces apoptosis in Jurkat cells, but the

- AMP-activated protein kinase is not involved. *Biochem J* 370:1027-32.
- Lovell JF, Billen LP, Bindner S, Shamas-Din A, Fradin C, Leber B, Andrews DW (2008): Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. *Cell* 135:1074-84.
- Luo J, Manning BD, Cantley LC (2003): Targeting the PI3K-Akt pathway in human cancer: rationale and promise. *Cancer Cell* 4:257-62.
- Macdonald A, Campbell DG, Toth R, McLauchlan H, Hastie CJ, Arthur JS (2006): Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. *BMC Cell Biol* 7:1.
- MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES (1997): Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. *J Biol Chem* 272:25417-20.
- MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, Cohen GM (2002): Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. *Oncogene* 21:6809-18.
- MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB, Dyer MJ, Cohen GM (2005): Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. *Cell Death Differ* 12:773-82.
- Majno G, Joris I (1995): Apoptosis, oncosis, and necrosis. An overview of cell death. *Am J Pathol* 146:3-15.
- Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N (2006): mTOR, translation initiation and cancer. *Oncogene* 25:6416-22.
- Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC (2002): Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberlin as a target of the phosphoinositide 3-kinase/akt pathway. *Mol Cell* 10:151-62.
- Mariani SM, Krammer PH (1998): Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. *Eur J Immunol* 28:973-82.
- Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L, Ruggeri A, Conte R, Cocco L (2003): A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. *Leukemia* 17:1794-805.
- Martinon F, Holler N, Richard C, Tschopp J (2000): Activation of a pro-apoptotic amplification loop through inhibition of NF-kappaB-dependent survival signals by caspase-mediated inactivation of RIP. *FEBS Lett* 468:134-6.
- Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM (2006): p53 regulates mitochondrial respiration. *Science* 312:1650-3.

- McBride A, Ghilagaber S, Nikolaev A, Hardie DG (2009): The glycogen-binding domain on the AMPK beta subunit allows the kinase to act as a glycogen sensor. *Cell Metab* 9:23-34.
- McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Basecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM (2008): Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. *Leukemia* 22:708-22.
- McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ (2001): Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. *Mol Cell Biol* 21:1249-59.
- Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH, Peter ME (1997): FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). *Embo J* 16:2794-804.
- Meisse D, Van de Casteele M, Beauloye C, Hainault I, Kefas BA, Rider MH, Fougere F, Hue L (2002): Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells. *FEBS Lett* 526:38-42.
- Meley D, Bauvy C, Houben-Weerts JH, Dubbelhuis PF, Helmond MT, Codogno P, Meijer AJ (2006): AMP-activated protein kinase and the regulation of autophagic proteolysis. *J Biol Chem* 281:34870-9.
- Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O (2006): Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. *Mol Cell Biol* 26:7046-55.
- Meurette O, Fontaine A, Rebillard A, Le Moigne G, Lamy T, Lagadic-Gossmann D, Dimanche-Boitrel MT (2006): Cytotoxicity of TRAIL/anticancer drug combinations in human normal cells. *Ann N Y Acad Sci* 1090:209-16.
- Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J (2001): NF-kappaB signals induce the expression of c-FLIP. *Mol Cell Biol* 21:5299-305.
- Micheau O, Tschopp J (2003): Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. *Cell* 114:181-90.
- Mita MM, Mita A, Rowinsky EK (2003): Mammalian target of rapamycin: a new molecular target for breast cancer. *Clin Breast Cancer* 4:126-37.
- Mizushima N, Yoshimori T (2007): How to interpret LC3 immunoblotting. *Autophagy* 3:542-5.
- Mollinedo F, Gajate C (2003): Microtubules, microtubule-interfering agents and apoptosis. *Apoptosis* 8:413-50.
- Momcilovic M, Hong SP, Carlson M (2006): Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. *J Biol Chem* 281:25336-43.

- Morel J, Audo R, Hahne M, Combe B (2005): Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. *J Biol Chem* 280:15709-18.
- Moreno D, Knecht E, Viollet B, Sanz P (2008): A769662, a novel activator of AMP-activated protein kinase, inhibits non-proteolytic components of the 26S proteasome by an AMPK-independent mechanism. *FEBS Lett* 582:2650-4.
- Moreno D, Viana R, Sanz P (2009): Two-hybrid analysis identifies PSMD11, a non-ATPase subunit of the proteasome, as a novel interaction partner of AMP-activated protein kinase. *Int J Biochem Cell Biol*.
- Morishima N, Nakanishi K, Takenouchi H, Shibata T, Yasuhiko Y (2002): An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. *J Biol Chem* 277:34287-94.
- Munoz-Pinedo C, Robledo G, Lopez-Rivas A (2004): Thymidylate synthase inhibition triggers glucose-dependent apoptosis in p53-negative leukemic cells. *FEBS Lett* 570:205-10.
- Munoz-Pinedo C, Ruiz-Ruiz C, Ruiz de Almodovar C, Palacios C, Lopez-Rivas A (2003): Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing. *J Biol Chem* 278:12759-68.
- Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ (2000): Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. *Cancer Res* 60:847-53.
- Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, Yuan J (2000): Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. *Nature* 403:98-103.
- Nakano K, Vousden KH (2001): PUMA, a novel proapoptotic gene, is induced by p53. *Mol Cell* 7:683-94.
- Nakashima K, Yakabe Y (2007): AMPK activation stimulates myofibrillar protein degradation and expression of atrophy-related ubiquitin ligases by increasing FOXO transcription factors in C2C12 myotubes. *Biosci Biotechnol Biochem* 71:1650-6.
- Nam SY, Amoscato AA, Lee YJ (2002): Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway. *Oncogene* 21:337-46.
- Neumann D, Woods A, Carling D, Wallimann T, Schlattner U (2003): Mammalian AMP-activated protein kinase: functional, heterotrimeric complexes by co-expression of subunits in *Escherichia coli*. *Protein Expr Purif* 30:230-7.
- Newsom-Davis T, Prieske S, Walczak H (2009): Is TRAIL the holy grail of cancer therapy? *Apoptosis* 14:607-23.

- Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN (2001): Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. *Cancer Res* 61:759-63.
- Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N (2000): Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. *Science* 288:1053-8.
- Okoshi R, Ozaki T, Yamamoto H, Ando K, Koida N, Ono S, Koda T, Kamijo T, Nakagawara A, Kizaki H (2008): Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. *J Biol Chem* 283:3979-87.
- Ortiz-Ferron G, Yerbes R, Eramo A, Lopez-Perez AI, De Maria R, Lopez-Rivas A (2008): Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. *Cell Res* 18:664-76.
- Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, Xu Y, Wonsey D, Lee LA, Dang CV (2000): Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. *J Biol Chem* 275:21797-800.
- Owen MR, Doran E, Halestrap AP (2000): Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. *Biochem J* 348 Pt 3:607-14.
- Padanilam BJ (2001): Induction and subcellular localization of protein kinase C isozymes following renal ischemia. *Kidney Int* 59:1789-97.
- Palacios C, Yerbes R, Lopez-Rivas A (2006): Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. *Cancer Res* 66:8858-69.
- Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM (1997a): An antagonist decoy receptor and a death domain-containing receptor for TRAIL. *Science* 277:815-8.
- Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM (1997b): The receptor for the cytotoxic ligand TRAIL. *Science* 276:1111-3.
- Pang T, Xiong B, Li JY, Qiu BY, Jin GZ, Shen JK, Li J (2007): Conserved alpha-helix acts as autoinhibitory sequence in AMP-activated protein kinase alpha subunits. *J Biol Chem* 282:495-506.
- Pang T, Zhang ZS, Gu M, Qiu BY, Yu LF, Cao PR, Shao W, Su MB, Li JY, Nan FJ, Li J (2008): Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. *J Biol Chem* 283:16051-60.
- Panner A, James CD, Berger MS, Pieper RO (2005): mTOR controls FLIPs translation and TRAIL sensitivity in glioblastoma multiforme cells. *Mol Cell Biol* 25:8809-23.

- Parker AL, McVey JH, Doctor JH, Lopez-Franco O, Waddington SN, Havenga MJ, Nicklin SA, Baker AH (2007): Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. *J Virol* 81:3627-31.
- Paschen W, Mengesdorf T (2005): Endoplasmic reticulum stress response and neurodegeneration. *Cell Calcium* 38:409-15.
- Pattingre S, Espert L, Biard-Piechaczyk M, Codogno P (2008): Regulation of macroautophagy by mTOR and Beclin 1 complexes. *Biochimie* 90:313-23.
- Pauley RJ, Soule HD, Tait L, Miller FR, Wolman SR, Dawson PJ, Heppner GH (1993): The MCF10 family of spontaneously immortalized human breast epithelial cell lines: models of neoplastic progression. *Eur J Cancer Prev* 2 Suppl 3:67-76.
- Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, Mueller M, Fumagalli S, Kozma SC, Thomas G (2004): S6K1(-)/S6K2(-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. *Mol Cell Biol* 24:3112-24.
- Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, Owen LB, Pope RM, Tschopp J, Wajant H, Wallach D, Wiltrout RH, Zornig M, Lynch DH (2007): The CD95 receptor: apoptosis revisited. *Cell* 129:447-50.
- Petros AM, Medek A, Nettlesheim DG, Kim DH, Yoon HS, Swift K, Matayoshi ED, Oltersdorf T, Fesik SW (2001): Solution structure of the antiapoptotic protein bcl-2. *Proc Natl Acad Sci U S A* 98:3012-7.
- Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A (1996): Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. *J Biol Chem* 271:12687-90.
- Polekhina G, Gupta A, Michell BJ, van Denderen B, Murthy S, Feil SC, Jennings IG, Campbell DJ, Witters LA, Parker MW, Kemp BE, Stapleton D (2003): AMPK beta subunit targets metabolic stress sensing to glycogen. *Curr Biol* 13:867-71.
- Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW (2004): Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. *Oncogene* 23:2934-49.
- Popivanova BK, Li YY, Zheng H, Omura K, Fujii C, Tsuneyama K, Mukaida N (2007): Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis. *Cancer Sci* 98:321-8.
- Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A (1999): The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. *Mol Cell* 3:287-96.
- Rasper DM, Vaillancourt JP, Hadano S, Houtzager VM, Seiden I, Keen SL, Tawa P, Xanthoudakis S, Nasir J, Martindale D, Koop BF, Peterson EP, Thornberry NA, Huang J, MacPherson DP, Black SC, Hornung

- F, Lenardo MJ, Hayden MR, Roy S, Nicholson DW (1998): Cell death attenuation by 'Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. *Cell Death Differ* 5:271-88.
- Rattan R, Giri S, Singh AK, Singh I (2005): 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. *J Biol Chem* 280:39582-93.
- Richter BW, Mir SS, Eiben LJ, Lewis J, Reffey SB, Frattini A, Tian L, Frank S, Youle RJ, Nelson DL, Notarangelo LD, Vezzoni P, Fearnhead HO, Duckett CS (2001): Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. *Mol Cell Biol* 21:4292-301.
- Roberts DL, Merrison W, MacFarlane M, Cohen GM (2001): The inhibitor of apoptosis protein-binding domain of Smac is not essential for its proapoptotic activity. *J Cell Biol* 153:221-8.
- Romagnoli M, Desplanques G, Maiga S, Legouill S, Dreano M, Bataille R, Barille-Nion S (2007): Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. *Clin Cancer Res* 13:6010-8.
- Rosato RR, Almenara JA, Dai Y, Grant S (2003): Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. *Mol Cancer Ther* 2:1273-84.
- Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV (1995): The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. *Cell* 83:1243-52.
- Roue G, Perez-Galan P, Lopez-Guerra M, Villamor N, Campo E, Colomer D (2007): Selective inhibition of I kappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. *J Immunol* 178:1923-30.
- Roy N, Mahadevan MS, McLean M, Shutler G, Yaraghi Z, Farahani R, Baird S, Besner-Johnston A, Lefebvre C, Kang X, et al. (1995): The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. *Cell* 80:167-78.
- Royds JA, Iacopetta B (2006): p53 and disease: when the guardian angel fails. *Cell Death Differ* 13:1017-26.
- Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A (2000): Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. *Cancer Res* 60:5673-80.
- Rupinder SK, Gurpreet AK, Manjeet S (2007): Cell suicide and caspases. *Vascul Pharmacol* 46:383-93.
- Russell RR, 3rd, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Giordano FJ, Mu J, Birnbaum MJ, Young LH (2004): AMP-activated protein

- kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. *J Clin Invest* 114:495-503.
- Ruvinsky I, Sharon N, Lerer T, Cohen H, Stolovich-Rain M, Nir T, Dor Y, Zisman P, Meyuhas O (2005): Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. *Genes Dev* 19:2199-211.
- Safa AR, Day TW, Wu CH (2008): Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. *Curr Cancer Drug Targets* 8:37-46.
- Salomoni P, Pandolfi PP (2002): The role of PML in tumor suppression. *Cell* 108:165-70.
- Salt I, Celler JW, Hawley SA, Prescott A, Woods A, Carling D, Hardie DG (1998): AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. *Biochem J* 334 (Pt 1):177-87.
- Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, Sabatini DM (2007): PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. *Mol Cell* 25:903-15.
- Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, Westra WH, Herman JG, Sidransky D (2002): Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. *Cancer Res* 62:3659-62.
- Sanders MJ, Ali ZS, Hegarty BD, Heath R, Snowden MA, Carling D (2007a): Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. *J Biol Chem* 282:32539-48.
- Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, Carling D (2007b): Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. *Biochem J* 403:139-48.
- Sanjo H, Takeda K, Tsujimura T, Ninomiya-Tsuji J, Matsumoto K, Akira S (2003): TAB2 is essential for prevention of apoptosis in fetal liver but not for interleukin-1 signaling. *Mol Cell Biol* 23:1231-8.
- Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM (2004): Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. *Curr Biol* 14:1296-302.
- Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM (2006): Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. *Mol Cell* 22:159-68.
- Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005): Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science* 307:1098-101.
- Scott JW, Hawley SA, Green KA, Anis M, Stewart G, Scullion GA, Norman DG, Hardie DG (2004): CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. *J Clin Invest* 113:274-84.

- Scott JW, van Denderen BJ, Jorgensen SB, Honeyman JE, Steinberg GR, Oakhill JS, Iseli TJ, Koay A, Gooley PR, Stapleton D, Kemp BE (2008): Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. *Chem Biol* 15:1220-30.
- Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI (1997): TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. *Curr Biol* 7:693-6.
- Scherer WF, Syverton JT, Gey GO (1953): Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. *J Exp Med* 97:695-710.
- Schmidt M, Budirahardja Y, Klompmaker R, Medema RH (2005): Ablation of the spindle assembly checkpoint by a compound targeting Mps1. *EMBO Rep* 6:866-72.
- Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding XZ, Adrian TE, Pour PM (2001): Prevention of pancreatic cancer induction in hamsters by metformin. *Gastroenterology* 120:1263-70.
- Schwartzberg-Bar-Yoseph F, Armoni M, Karnieli E (2004): The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. *Cancer Res* 64:2627-33.
- Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, Zauli G (2003): TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. *Circulation* 107:2250-6.
- Semenza GL (2000): HIF-1: mediator of physiological and pathophysiological responses to hypoxia. *J Appl Physiol* 88:1474-80.
- Shah OJ, Wang Z, Hunter T (2004): Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. *Curr Biol* 14:1650-6.
- Shankar S, Chen X, Srivastava RK (2005): Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. *Prostate* 62:165-86.
- Shankar S, Singh TR, Srivastava RK (2004): Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. *Prostate* 61:35-49.
- Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC (2004): The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. *Proc Natl Acad Sci U S A* 101:3329-35.
- Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A (1997): Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. *Science* 277:818-21.

- Shi B, Tran T, Sobkoviak R, Pope RM (2009): Activation-induced degradation of FLIP(L) is mediated via the phosphatidylinositol 3-kinase/Akt signaling pathway in macrophages. *J Biol Chem* 284:14513-23.
- Shi Y (2002): Mechanisms of caspase activation and inhibition during apoptosis. *Mol Cell* 9:459-70.
- Shibuya H, Yamaguchi K, Shirakabe K, Tonegawa A, Gotoh Y, Ueno N, Irie K, Nishida E, Matsumoto K (1996): TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. *Science* 272:1179-82.
- Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R, Dang CV (1997): c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. *Proc Natl Acad Sci U S A* 94:6658-63.
- Siegel RM, Chan FK, Chun HJ, Lenardo MJ (2000): The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. *Nat Immunol* 1:469-74.
- Sim AT, Hardie DG (1988): The low activity of acetyl-CoA carboxylase in basal and glucagon-stimulated hepatocytes is due to phosphorylation by the AMP-activated protein kinase and not cyclic AMP-dependent protein kinase. *FEBS Lett* 233:294-8.
- Skaug B, Jiang X, Chen ZJ (2009): The role of ubiquitin in NF-kappaB regulatory pathways. *Annu Rev Biochem* 78:769-96.
- Smith CA, Farrah T, Goodwin RG (1994): The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. *Cell* 76:959-62.
- Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H (2003): Nature's TRAIL—on a path to cancer immunotherapy. *Immunity* 18:1-6.
- Soule HD, Vazquez J, Long A, Albert S, Brennan M (1973): A human cell line from a pleural effusion derived from a breast carcinoma. *J Natl Cancer Inst* 51:1409-16.
- Stapleton D, Mitchelhill KI, Gao G, Widmer J, Michell BJ, Teh T, House CM, Fernandez CS, Cox T, Witters LA, Kemp BE (1996): Mammalian AMP-activated protein kinase subfamily. *J Biol Chem* 271:611-4.
- Stein SC, Woods A, Jones NA, Davison MD, Carling D (2000): The regulation of AMP-activated protein kinase by phosphorylation. *Biochem J* 345 Pt 3:437-43.
- Steiner DF, Williams RH (1958): Respiratory inhibition and hypoglycemia by biguanides and decamethylenediguanidine. *Biochim Biophys Acta* 30:329-40.
- Su RY, Chao Y, Chen TY, Huang DY, Lin WW (2007): 5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNF{alpha}-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling. *Mol Cancer Ther* 6:1562-71.
- Sun SY, Yue P, Hong WK, Lotan R (2000): Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through

- up-regulation of TRAIL receptors in human lung cancer cells. *Cancer Res* 60:7149-55.
- Susín SA, Daugas E, Ravagnan L, Samejima K, Zamzami N, Loeffler M, Costantini P, Ferri KF, Irinopoulou T, Prevost MC, Brothers G, Mak TW, Penninger J, Earnshaw WC, Kroemer G (2000): Two distinct pathways leading to nuclear apoptosis. *J Exp Med* 192:571-80.
- Susín SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G (1999): Molecular characterization of mitochondrial apoptosis-inducing factor. *Nature* 397:441-6.
- Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K, Takahashi R (2001): A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. *Mol Cell* 8:613-21.
- Swinnen JV, Beckers A, Brusselmans K, Organe S, Segers J, Timmermans L, Vanderhoydonc F, Deboel L, Derua R, Waelkens E, De Schrijver E, Van de Sande T, Noel A, Fougelle F, Verhoeven G (2005): Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. *Cancer Res* 65:2441-8.
- Tada K, Okazaki T, Sakon S, Kobarai T, Kurosawa K, Yamaoka S, Hashimoto H, Mak TW, Yagita H, Okumura K, Yeh WC, Nakano H (2001): Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death. *J Biol Chem* 276:36530-4.
- Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, Salvesen GS, Reed JC (1998): A single BIR domain of XIAP sufficient for inhibiting caspases. *J Biol Chem* 273:7787-90.
- Takeda K, Lin J, Okubo S, Akazawa-Kudoh S, Kajinami K, Kanemitsu S, Tsugawa H, Kanda T, Matsui S, Takekoshi N (2004a): Transient glucose deprivation causes upregulation of heme oxygenase-1 and cyclooxygenase-2 expression in cardiac fibroblasts. *J Mol Cell Cardiol* 36:821-30.
- Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, Sayers TJ, Seki N, Okumura K, Yagita H, Smyth MJ (2004b): Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. *J Exp Med* 199:437-48.
- Taylor RC, Cullen SP, Martin SJ (2008): Apoptosis: controlled demolition at the cellular level. *Nat Rev Mol Cell Biol* 9:231-41.
- Tennant DA, Duran RV, Boulahbel H, Gottlieb E (2009): Metabolic transformation in cancer. *Carcinogenesis* 30:1269-80.
- Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK (2001): Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance. *J Biol Chem* 276:38361-9.
- Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schroter M, Scaffidi C, Kramer PH, Peter ME, Tschopp J (1997): Viral FLICE-inhibitory proteins

- (FLIPs) prevent apoptosis induced by death receptors. *Nature* 386:517-21.
- Thornton C, Snowden MA, Carling D (1998): Identification of a novel AMP-activated protein kinase beta subunit isoform that is highly expressed in skeletal muscle. *J Biol Chem* 273:12443-50.
- Tinel A, Tschopp J (2004): The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. *Science* 304:843-6.
- Tong JF, Yan X, Zhu MJ, Du M (2009): AMP-activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1/Akt signaling in C2C12 myotubes. *J Cell Biochem* 108:458-68.
- Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D, Emme D, Roder C, Kalthoff H, Wajant H (2006): TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. *Oncogene* 25:7434-9.
- Treebak JT, Birk JB, Hansen BF, Olsen GS, Wojtaszewski JF (2009): A-769662 activates AMPK {beta}1-containing complexes but induces glucose uptake through a PI3 kinase-dependent pathway in mouse skeletal muscle. *Am J Physiol Cell Physiol*.
- Trompouki E, Hatzivassiliou E, Tschirzitis T, Farmer H, Ashworth A, Mosialos G (2003): CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. *Nature* 424:793-6.
- Turnley AM, Stapleton D, Mann RJ, Witters LA, Kemp BE, Bartlett PF (1999): Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system. *J Neurochem* 72:1707-16.
- Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, Thomas G (2004): Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. *Nature* 431:200-5.
- Upton JP, Austgen K, Nishino M, Coakley KM, Hagen A, Han D, Papa FR, Oakes SA (2008): Caspase-2 cleavage of BID is a critical apoptotic signal downstream of endoplasmic reticulum stress. *Mol Cell Biol* 28:3943-51.
- Uren AG, Pakusch M, Hawkins CJ, Puls KL, Vaux DL (1996): Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. *Proc Natl Acad Sci U S A* 93:4974-8.
- Vandenabeele P, Declercq W, Beyaert R, Fiers W (1995): Two tumour necrosis factor receptors: structure and function. *Trends Cell Biol* 5:392-9.
- Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH (2007): Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. *Nat Cell Biol* 9:316-23.
- Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, Ashkenazi A (2005): Molecular determinants of kinase pathway

- activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. *J Biol Chem* 280:40599-608.
- Varfolomeev E, Vucic D (2008): (Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways. *Cell Cycle* 7:1511-21.
- Varfolomeev EE, Ashkenazi A (2004): Tumor necrosis factor: an apoptosis JuNKie? *Cell* 116:491-7.
- Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA (2009): The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. *Cell Cycle* 8:88-96.
- Vercammen D, Beyaert R, Denecker G, Goossens V, Van Loo G, Declercq W, Grooten J, Fiers W, Vandenabeele P (1998a): Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. *J Exp Med* 187:1477-85.
- Vercammen D, Brouckaert G, Denecker G, Van de Craen M, Declercq W, Fiers W, Vandenabeele P (1998b): Dual signaling of the Fas receptor: initiation of both apoptotic and necrotic cell death pathways. *J Exp Med* 188:919-30.
- Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL (2000): Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. *Cell* 102:43-53.
- Verhagen AM, Silke J, Ekert PG, Pakusch M, Kaufmann H, Connolly LM, Day CL, Tikoo A, Burke R, Wrobel C, Moritz RL, Simpson RJ, Vaux DL (2002): HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. *J Biol Chem* 277:445-54.
- Vernia S, Solaz-Fuster MC, Gimeno-Alcaniz JV, Rubio T, Garcia-Haro L, Foretz M, de Cordoba SR, Sanz P (2009): AMP-activated protein kinase phosphorylates R5/PTG, the glycogen targeting subunit of the R5/PTG-protein phosphatase 1 holoenzyme, and accelerates its down-regulation by the laforin-malin complex. *J Biol Chem* 284:8247-55.
- Viana R, Aguado C, Esteban I, Moreno D, Viollet B, Knecht E, Sanz P (2008): Role of AMP-activated protein kinase in autophagy and proteasome function. *Biochem Biophys Res Commun* 369:964-8.
- Villen J, Beausoleil SA, Gerber SA, Gygi SP (2007): Large-scale phosphorylation analysis of mouse liver. *Proc Natl Acad Sci U S A* 104:1488-93.
- Vincent MF, Marangos PJ, Gruber HE, Van den Berghe G (1991): Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. *Diabetes* 40:1259-66.
- Vogelstein B, Kinzler KW (2004): Cancer genes and the pathways they control. *Nat Med* 10:789-99.
- Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM (2000): ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. *Curr Biol* 10:1359-66.

- Wajant H, Pfizenmaier K, Scheurich P (2003): Tumor necrosis factor signaling. *Cell Death Differ* 10:45-65.
- Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT (1997): TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. *Embo J* 16:5386-97.
- Walker KS, Deak M, Paterson A, Hudson K, Cohen P, Alessi DR (1998): Activation of protein kinase B beta and gamma isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase B alpha. *Biochem J* 331 (Pt 1):299-308.
- Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ (2001): TAK1 is a ubiquitin-dependent kinase of MKK and IKK. *Nature* 412:346-51.
- Wang GL, Jiang BH, Rue EA, Semenza GL (1995): Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. *Proc Natl Acad Sci U S A* 92:5510-4.
- Wang L, Du F, Wang X (2008): TNF-alpha induces two distinct caspase-8 activation pathways. *Cell* 133:693-703.
- Wang X (2001): The expanding role of mitochondria in apoptosis. *Genes Dev* 15:2922-33.
- Warburg O (1956): On the origin of cancer cells. *Science* 123:309-14.
- Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, Thompson CB, Korsmeyer SJ (2000): tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. *Genes Dev* 14:2060-71.
- Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K (2000): Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. *Blood* 96:3900-6.
- Wicovsky A, Siegmund D, Wajant H (2005): Interferons induce proteolytic degradation of TRAILR4. *Biochem Biophys Res Commun* 337:184-90.
- Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al. (1995): Identification and characterization of a new member of the TNF family that induces apoptosis. *Immunity* 3:673-82.
- Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Ierino H, Lee EF, Fairlie WD, Bouillet P, Strasser A, Kluck RM, Adams JM, Huang DC (2007): Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. *Science* 315:856-9.
- Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T, Shimamura T, Miller DS, Sharpless NE, Bardeesy N, Kwiatkowski DJ, Schorge JO, Wong KK, Castrillon DH (2009): Somatic LKB1 mutations promote cervical cancer progression. *PLoS One* 4:2.
- Wojtaszewski JF, Jorgensen SB, Hellsten Y, Hardie DG, Richter EA (2002): Glycogen-dependent effects of 5-aminoimidazole-4-carboxamide

- (AICA)-riboside on AMP-activated protein kinase and glycogen synthase activities in rat skeletal muscle. *Diabetes* 51:284-92.
- Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ (1997): Movement of Bax from the cytosol to mitochondria during apoptosis. *J Cell Biol* 139:1281-92.
- Woods A, Azzout-Marniche D, Foretz M, Stein SC, Lemarchand P, Ferre P, Foufelle F, Carling D (2000): Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. *Mol Cell Biol* 20:6704-11.
- Woods A, Cheung PC, Smith FC, Davison MD, Scott J, Beri RK, Carling D (1996a): Characterization of AMP-activated protein kinase beta and gamma subunits. Assembly of the heterotrimeric complex in vitro. *J Biol Chem* 271:10282-90.
- Woods A, Dickerson K, Heath R, Hong SP, Momcilovic M, Johnstone SR, Carlson M, Carling D (2005): Ca²⁺/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. *Cell Metab* 2:21-33.
- Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M, Carling D (2003): LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. *Curr Biol* 13:2004-8.
- Woods A, Salt I, Scott J, Hardie DG, Carling D (1996b): The alpha1 and alpha2 isoforms of the AMP-activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro. *FEBS Lett* 397:347-51.
- Wu CJ, Conze DB, Li T, Srinivasula SM, Ashwell JD (2006): Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected]. *Nat Cell Biol* 8:398-406.
- Wu GS, Burns TF, McDonald ER, 3rd, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, el-Deiry WS (1997): KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. *Nat Genet* 17:141-3.
- Wyllie AH (1980): Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. *Nature* 284:555-6.
- Xia ZP, Sun L, Chen X, Pineda G, Jiang X, Adhikari A, Zeng W, Chen ZJ (2009): Direct activation of protein kinases by unanchored polyubiquitin chains. *Nature*.
- Xiao B, Heath R, Saiu P, Leiper FC, Leone P, Jing C, Walker PA, Haire L, Eccleston JF, Davis CT, Martin SR, Carling D, Gamblin SJ (2007): Structural basis for AMP binding to mammalian AMP-activated protein kinase. *Nature* 449:496-500.
- Xie M, Zhang D, Dyck JR, Li Y, Zhang H, Morishima M, Mann DL, Taffet GE, Baldini A, Khoury DS, Schneider MD (2006a): A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-

- activated protein kinase energy-sensor pathway. *Proc Natl Acad Sci U S A* 103:17378-83.
- Xie Z, Dong Y, Scholz R, Neumann D, Zou MH (2008a): Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. *Circulation* 117:952-62.
- Xie Z, Dong Y, Zhang M, Cui MZ, Cohen RA, Riek U, Neumann D, Schlattner U, Zou MH (2006b): Activation of protein kinase C zeta by peroxynitrite regulates LKB1-dependent AMP-activated protein kinase in cultured endothelial cells. *J Biol Chem* 281:6366-75.
- Xie Z, Nair U, Klionsky DJ (2008b): Atg8 controls phagophore expansion during autophagosome formation. *Mol Biol Cell* 19:3290-8.
- Yamaguchi H, Wang HG (2004): CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. *J Biol Chem* 279:45495-502.
- Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E, Matsumoto K (1995): Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. *Science* 270:2008-11.
- Yang JK (2008): FLIP as an anti-cancer therapeutic target. *Yonsei Med J* 49:19-27.
- Yang S, Thor AD, Edgerton S, Yang X (2006): Caspase-3 mediated feedback activation of apical caspases in doxorubicin and TNF-alpha induced apoptosis. *Apoptosis* 11:1987-97.
- Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD (2000): Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. *Science* 288:874-7.
- Yeh WC, Itie A, Elia AJ, Ng M, Shu HB, Wakeham A, Mirtsos C, Suzuki N, Bonnard M, Goeddel DV, Mak TW (2000): Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. *Immunity* 12:633-42.
- Yethon JA, Epand RF, Leber B, Epand RM, Andrews DW (2003): Interaction with a membrane surface triggers a reversible conformational change in Bax normally associated with induction of apoptosis. *J Biol Chem* 278:48935-41.
- Yeung SJ, Pan J, Lee MH (2008): Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. *Cell Mol Life Sci* 65:3981-99.
- Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T (2005): Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. *Cancer Res* 65:5662-7.
- Young LH (2009): A crystallized view of AMPK activation. *Cell Metab* 10:5-6.
- Yu H, Fujii N, Hirshman MF, Pomerleau JM, Goodyear LJ (2004): Cloning and characterization of mouse 5'-AMP-activated protein kinase gamma3 subunit. *Am J Physiol Cell Physiol* 286:24.

- Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, Poirier GG, Dawson TM, Dawson VL (2002): Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. *Science* 297:259-63.
- Yu X, Wang L, Acehan D, Wang X, Akey CW (2006): Three-dimensional structure of a double apoptosome formed by the *Drosophila* Apaf-1 related killer. *J Mol Biol* 355:577-89.
- Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR (1993): The *C. elegans* cell death gene *ced-3* encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. *Cell* 75:641-52.
- Yun H, Kim HS, Lee S, Kang I, Kim SS, Choe W, Ha J (2009): AMP kinase signaling determines whether c-Jun N-terminal kinase promotes survival or apoptosis during glucose deprivation. *Carcinogenesis* 30:529-37.
- Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006): Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. *Cancer Res* 66:10269-73.
- Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN (2008): The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. *Cancer Prev Res (Phila Pa)* 1:369-75.
- Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ (1996): Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). *Cell* 87:619-28.
- Zhang XD, Gillespie SK, Borrow JM, Hersey P (2003): The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. *Biochem Pharmacol* 66:1537-45.
- Zhang Y, Zhang B (2008): TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. *Mol Cancer Res* 6:1861-71.
- Zong WX, Thompson CB (2006): Necrotic death as a cell fate. *Genes Dev* 20:1-15.